Altimmune plummets following release of pemvidutide study results Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Nikola (NKLA) up 3% after BTIG analyst Gregory Lewis upgraded shares to Buy with a $12 price target
- Johnson & Johnson (JNJ) up 1% after announcing a $5B share repurchase program
- SoFi Technologies (SOFI) up 4% after BofA analyst Mihir Bhatia upgraded the stock to Buy with a price target of $9, up from $8
- Starbucks (SBUX) up 1% after the company gave updated FY23-FY25 financial targets at yesterday's investor day meeting
UP AFTER EARNINGS -
DOWN AFTER EARNINGS -
- Rail Vision (RVSN) down 12%
- Nucor (NUE) down 6%
- Li-Cycle (LICY) down 1%
LOWER -
- Altimmune (ALT) down 50% after reporting results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease
- Union Pacific (UNP) and CSX (CSX) both down 1% after Bernstein analyst David Vernon downgraded both stocks to Market Perform from Outperform
- Dow Inc. (DOW) down 2% after issuing a warning on its Q3 results in slides for a conference presentation
Symbols:
NKLA JNJ SOFI SBUX DOOO RVSN NUE LICY ALT UNP CSX DOW Keywords: Fly Intel, Wall Street, Top Stories, Stocks